Raltegravir-d6雷特格韦-d6,1100750-98-8产品图

Raltegravir-d6雷特格韦-d6,1100750-

98-8
收藏
  • 询价
  • MedChemExpress(MCE)已认证
  • 美国
  • HY-10353S1
  • 2025年12月05日
    avatar
    品牌商
    14钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      Please store the product under the recommended conditions in the Certificate of Analysis.

    • 英文名

      MK-0518-d<sub>6</sub>

    • 库存

      货期:询盘

    • 供应商

      MedChemExpress LLC

    • CAS号

      1100750-98-8

    • 规格

      1 mg

    Raltegravir-d6 产品活性:Raltegravir-d6是氘代标记的Raltegravir。Raltegravir(MK0518)是HIV整合酶(IN)抑制剂。 产品来源: www.medchemexpress.cn/raltegravir-d6.html 研究领域:Others | Anti-infection | Metabolic Enzyme/Protease 作用靶点:Isotope-Labeled Compounds | HIV | HIV Integrase In Vitro: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication. In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range. In Vivo: Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy. 相关产品:Chloroquine | Doxorubicin hydrochloride | 5-Fluorouracil | Q-VD-OPh | Valproic acid | Panobinostat | Shikonin | Probenecid | Dimethyl fumarate | Hydroxyurea | Kaempferol | Plerixafor | Baicalin | Maraviroc | Birinapant | Flavopiridol | Ritonavir | Ivermectin | Ebselen | Fasudil Hydrochloride | Rolipram | Lysozyme from chicken egg white | CK-666 | Rottlerin | Oleanolic acid | Betulinic acid | Scutellarin 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;设有专业的实验中心和严格的质控、验证体系;提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;产品的生物活性多经各国客户实验验证;Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果;专业团队跟踪前沿的制药及生命科学研究进展,为您提供全球前沿的活性化合物;与世界各大制药公司及知名科研机构建立了长期的合作。

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    •  拉丁方设计资料的方差分析

      网络     第四节 拉丁方设计资料的方差分析 表8.11 家兔注射某种药物后不同部位所生疱疹大小(cm 2 ) 动物编号 注射次序 各动物 小 计 各动物 平均数 1 2 3 4 5 6 Ⅰ B7.5 C6.7 A7.9 D6.1 F7.3 E6.9 41.4 7.07 Ⅱ E8.5 D8.2

    • 【共享】慢病毒载体

      0tFmKLLbbYrdioKIqKggkiCijNfnMukhJLLTXneVZ27z35O+vu7JwJJRkVcGECTIAJMAEmwASYgIIIKCtoHB6GCTABJsAEmAATYAISARY++I3ABJgAE2ACTIAJKJQACx8Kxc2DMQEmwASYABNgAix88HuACTABJsAEmAATUCgBFj4UipsHYwJMgAkwASbABFj44PcAE2ACTIAJMAEmoFACLHwoFDcPxgSYABNgAkyACbDwwe8BJsAEmAATYAJMQKEEWPhQKG4ejAkwASbABJgAE2Dhg98

    • (共享)免疫组化常用标记抗体

      +/++/--/+-/- 25-89%11-63%0-4%0-8%Esophagus squamous cell carcinoma +/--/- 21%79%Salivary gland tumor +/- 100%Epithelioid sarcoma -/- 100%Thyroid follicular, papillary and medullary carcinoma +/--/- 98%2%Thymus thymoma -/- 100%CK5/6 (cytokeratins

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    MedChemExpress LLC
    2025年12月05日询价
    询价
    西宝生物科技(上海)股份有限公司
    2025年06月06日询价
    ¥2573
    爱必信(上海)生物科技有限公司
    2025年11月15日询价
    询价
    北京柏瑞图科技有限公司
    2026年02月19日询价
    询价
    北京孚博生物科技有限公司
    2025年07月19日询价
    Raltegravir-d6雷特格韦-d6,1100750-98-8
    询价